| References: |
KC7F2 is a potent HIF-1 pathway inhibitor and that its potential as a cancer therapy agent warrants further study.
KC7F2 is the second HIF-1α inhibitor. KC7F2 is shown to inhibit the proliferation of cancer cells, an effect that is increased in hypoxia, while non-tumor cells are less sensitive. KC7F2 decreases HIF-1α levels by downregulating HIF-1α protein synthesis. KC7F2 markedly inhibits HIF-mediated transcription in cells derived from different tumor types, including glioma, breast and prostate cancers and exhibited enhanced cytotoxicity under hypoxia. KC7F2 prevents the activation of HIF-target genes such as Carbonic Anhydrase IX, Matrix Metalloproteinase 2 (MMP2), Endothelin 1 and Enolase 1. KC7F2 works through the down-regulation of HIF-1α protein synthesis, an effect accompanied by the suppression of the phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) and p70 S6 kinase (S6K), key regulators of HIF-1α protein synthesis. For the detailed information of KC7F2, the solubility of KC7F2 in water, the solubility of KC7F2 in DMSO, the solubility of KC7F2 in PBS buffer, the animal experiment (test) of KC7F2, the cell expriment (test) of KC7F2, the in vivo, in vitro and clinical trial test of KC7F2, the EC50, IC50,and affinity,of KC7F2, For the detailed information of KC7F2, the solubility of KC7F2 in water, the solubility of KC7F2 in DMSO, the solubility of KC7F2 in PBS buffer, the animal experiment (test) of KC7F2, the cell expriment (test) of KC7F2, the in vivo, in vitro and clinical trial test of KC7F2, the EC50, IC50,and affinity,of KC7F2, Please contact DC Chemicals. |
